Success Story: Indian Research Associate Earns EB-1A Approval for Advancing Global Health and Heart Disease Treatment
Client’s Testimonial:
“I have nothing but high praises for the team that handled both my EB2-NIW and EB1A petitions. Before signing the contract, the team was clear about what they would require me to add to my CV. They also carefully guided me on the people I should reach out to for my LoRs, who had never worked with me. While my EB1 petition initially got rejected, the Attorneys provided clear options on the paths I could take, eventually leading to an approval. Their reverts always came within 24 business hours, as was stated in the contract. I hope to receive notification on my EB2-NIW soon as well, so we are able to capture an earlier priority date, which was the strategy recommended by the Attorneys at Chen. Thank you so much for your guidance on such an important step in our journeys, Chen and Associates.”
On January 10th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Associate in the field of Cardiovascular Research (Approval Notice).
General Field: Cardiovascular Research
Position at the Time of Case Filing: Research Associate
Country of Origin: India
State of Residence at the Time of Filing: Ohio
Approval Notice Date: January 10th, 2025
Processing Time: 14 days (Premium Processing Requested)
Case Summary:
We are pleased to share the EB1A approval of a research associate from India. At the time of filing, the client was conducting research in the United States focused on global and national trends in cardiovascular care, healthcare disparities, and patient outcomes. His studies have shaped clinical strategies for coronary angiography, cardiac arrest management, and transcatheter aortic valve replacement (TAVR). With an exceptional publication record, high citation impact, and international recognition, he demonstrated extraordinary ability in his field.
Extraordinary Research Contributions
The client’s research provides vital insight into treatment optimization and healthcare equity in cardiovascular medicine. His findings have informed global medical guidelines and influenced clinical practices for managing cardiac arrest and heart failure. He has led landmark analyses that refined approaches to same-day discharge following TAVR, optimized cerebral protection during cardiac interventions, and improved the management of coronary artery disease. Collectively, his work advances patient safety, procedural efficiency, and equitable access to cardiovascular care, addressing a major public health priority in the United States.
Academic Record and Recognition
The client holds an M.B.B.S. and serves as a research associate at a leading U.S. institution. He has authored 54 peer-reviewed journal articles, 50 conference abstracts, and 2 book chapters, earning over 1,100 citations from scholars in 63 countries. Thirteen of his papers rank among the top 10% most cited in Clinical Medicine.
He has completed 17 peer reviews for major journals and serves on the editorial boards of BMC Cardiovascular Disorders, Frontiers in Nephrology, and European Journal of Medical Research. His research has also received funding from the Bill & Melinda Gates Foundation, further demonstrating its global impact.
Expert Recognition
Independent experts praised the importance of his research to U.S. healthcare and global innovation.
One recommender stated:
“It is clear that [client] stands at the top of his field, given his achievements in areas such as closing gaps in healthcare access in the United States and uncovering the advantages and disadvantages of TAVR.”
This endorsement highlights both the clinical and societal relevance of his contributions.
EB1A Approval and Outlook
The I-140 EB1A petition was filed on December 27, 2024, and approved on January 10, 2025, under premium processing. With NAILG’s support, the client demonstrated sustained international acclaim and major contributions to cardiovascular medicine. He now continues his work in the United States, developing data-driven strategies to improve heart disease prevention and healthcare delivery, reinforcing America’s leadership in global medical research.